MannKind (NASDAQ:MNKD) Earns “Sector Perform” Rating from Royal Bank Of Canada

MannKind (NASDAQ:MNKD)‘s stock had its “sector perform” rating reissued by Royal Bank Of Canada in a research report issued to clients and investors on Friday, Marketbeat.com reports. They presently have a $3.50 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 8.02% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reissued a “hold (c)” rating on shares of MannKind in a research report on Thursday, January 22nd. Wells Fargo & Company dropped their target price on MannKind from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Truist Financial set a $9.00 price target on MannKind in a research note on Monday, November 24th. Leerink Partners initiated coverage on MannKind in a report on Thursday, November 13th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of MannKind in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.36.

MannKind Price Performance

MNKD opened at $3.24 on Friday. The business has a fifty day moving average price of $5.61 and a 200 day moving average price of $5.35. MannKind has a 12 month low of $2.93 and a 12 month high of $6.51. The stock has a market capitalization of $994.91 million, a price-to-earnings ratio of 32.40 and a beta of 0.84.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). MannKind had a negative return on equity of 49.33% and a net margin of 9.32%.The company had revenue of $111.96 million for the quarter, compared to analyst estimates of $99.85 million. During the same period in the prior year, the firm posted $0.03 earnings per share. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. On average, research analysts anticipate that MannKind will post 0.1 earnings per share for the current year.

Insider Transactions at MannKind

In other MannKind news, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the completion of the sale, the insider directly owned 985,007 shares of the company’s stock, valued at $6,235,094.31. This represents a 4.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael Castagna sold 65,804 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $6.01, for a total value of $395,482.04. Following the sale, the chief executive officer owned 2,504,792 shares of the company’s stock, valued at $15,053,799.92. This trade represents a 2.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 262,846 shares of company stock valued at $1,546,840 over the last ninety days. Corporate insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd raised its stake in shares of MannKind by 108.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 2,927 shares during the last quarter. Quaker Wealth Management LLC increased its holdings in MannKind by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 7,000 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 14,000 shares in the last quarter. International Assets Investment Management LLC purchased a new position in MannKind during the 4th quarter valued at about $45,000. Huntington National Bank raised its position in MannKind by 420.0% during the fourth quarter. Huntington National Bank now owns 10,400 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Burkett Financial Services LLC purchased a new stake in shares of MannKind in the fourth quarter valued at about $59,000. 49.55% of the stock is owned by hedge funds and other institutional investors.

More MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Heavy call-option buying suggests some traders are positioning for an upside move in MNKD; unusual volume in calls (several thousand contracts) was reported. Read More.
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating with an $11 price target, signaling at least one analyst expects substantial upside vs. current levels. Read More.
• Positive Sentiment: Management highlighted a roughly $450M 2026 revenue run‑rate and key product catalysts, and is preparing for an Afrezza pediatric launch — items investors may view as multi‑quarter growth drivers. Read More.
• Neutral Sentiment: Company released Q4 materials, slide deck and an earnings‑call transcript — useful for investors doing deeper due diligence on unit trends and pipeline cadence. Read More.
• Neutral Sentiment: Analyst/coverage pieces break down the quarter: revenue beat consensus (≈$112M vs. $99.8M est.) and sales growth was strong year-over-year, but key per‑share metrics warrant attention. Read More.
• Negative Sentiment: EPS missed expectations: MannKind reported a $0.05 loss per share vs. consensus of a $0.01 loss, and that surprise to the downside drove downside sentiment and was cited as the main reason shares fell. Read More.
• Negative Sentiment: Market headlines flagged an unexpected Q4 loss and the stock hit a 52‑week low on the earnings news, which tends to amplify selling pressure from momentum-focused traders. Read More.
• Negative Sentiment: Competitive risk: shares were pressured by reports United Therapeutics is considering a new treprostinil formulation, which could affect market dynamics for some pulmonary-hypertension related products. Read More.

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.